Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TN...

Full description

Bibliographic Details
Main Authors: Sara Salvador-Martín, Irene Raposo-Gutiérrez, Víctor Manuel Navas-López, Carmen Gallego-Fernández, Ana Moreno-Álvarez, Alfonso Solar-Boga, Rosana Muñoz-Codoceo, Lorena Magallares, Eva Martínez-Ojinaga, María J. Fobelo, Antonio Millán-Jiménez, Alejandro Rodriguez-Martinez, Concepción A. Vayo, Cesar Sánchez, Mar Tolin, Ferrán Bossacoma, Gemma Pujol-Muncunill, Rafael González de Caldas, Inés Loverdos, José A. Blanca-García, Oscar Segarra, Francisco J. Eizaguirre, Ruth García-Romero, Vicente Merino-Bohórquez, María Sanjurjo-Sáez, Luis A. López-Fernández
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:International Journal of Molecular Sciences
Subjects:
biomarker
gene expression
infliximab
adalimumab
ulcerative colitis
Crohn’s disease
Online Access:https://www.mdpi.com/1422-0067/21/9/3364

Internet

https://www.mdpi.com/1422-0067/21/9/3364

Similar Items